Real-World Findings Reinforce Encelto’s Role in MacTel Treatment - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Real-World Findings Reinforce Encelto’s Role in MacTel Treatment

Roger A. Goldberg, MD, MBA, shared early postapproval experience with Encelto, including an evolving surgical technique, at Clinical Trials at the Summit.

  • By

  • Jim Gallagher, senior managing editor

  • June 1, 2026

  • 4 min

Share

Objective:

To present early postapproval experiences and outcomes associated with Encelto in the treatment of macular telangiectasia type 2 (MacTel).

Approach:
    Key Findings:
    • Pooled data from three randomized, sham-controlled studies demonstrated a 36% reduction in photoreceptor loss over two years.
    • Treatment resulted in a 68% reduction in the loss of monocular reading speed and a 35% reduction in retinal sensitivity loss compared to controls.
    • Real-world safety findings were consistent with clinical trials, with approximately 20% of patients experiencing mild delayed dark adaptation and miosis.
    Interpretation:

    Younger patients, those with smaller areas of ellipsoid zone loss, and those without foveal involvement are identified as the strongest responders to Encelto.

    Limitations:
    • Patient selection remains crucial, with recommendations based on structural evidence, symptoms, and disease progression.
    Conclusion:

    Encelto appears to address a longstanding treatment gap for patients with MacTel.

    Sources:

Original Source(s)

Real-World Findings Reinforce Encelto’s Role in MacTel Treatment

  • by Jim Gallagher, senior managing editor

  • June 1, 2026

Related Content

2026 Retina World Congress Preview

Baruch D. Kuppermann, MD, PhD, highlights the global focus and broad retina agenda of the upcoming Retina World Congress meeting in Fort Lauderdale.

Recognizing MacTel Masquerades

Imaging features such as retinal thinning and ellipsoid zone loss can help differentiate MacTel from AMD and related retinal diseases.

Retinal Imaging Model Aids CAD Detection

Fundus-based model showed moderate-to-good accuracy and improved performance when combined with clinical risk factors in a high-risk cohort